Gaxos.ai Inc. filings document a Nevada technology issuer with Nasdaq-listed common stock and emerging growth company status. Its 8-K reports cover material definitive agreements, at-the-market common stock sales arrangements, prospectus supplements and other events tied to equity financing and strategic investments, including the membership-interest purchase agreement for America First Defense.
Proxy and shareholder-meeting filings describe board elections, auditor ratification, equity incentive plan amendments and voting results. The filing record also identifies the GXAI common stock class, par value and exchange listing, and provides formal disclosures around governance, capitalization and securities issuance activity.
Gaxos.ai reported initial commercial revenue while continuing product investments and recording operating losses. Revenue was $170,971 in Q2 2025 and $194,703 for the six months, driven primarily by RNK Health administrative services ($170,398 Q2; $192,950 six months). The company recorded a net loss of $824,572 for the quarter and $2,056,634 year-to-date, driven by research and development and general and administrative costs of $1,153,665 in Q2.
On the balance sheet, cash declined to $1,718,964 from $14,398,099 at December 31, 2024, after purchasing short-term investments that rose to $12,326,666. Working capital remained positive at $13,992,440, and management states these resources should be sufficient to meet operating needs for the next 12 months. The company recorded a $748,000 intangible asset acquisition funded with $500,000 cash and 200,000 shares valued at $248,000.